ArticleArchives of toxicology2025
Gestational vortioxetine exposure impairs pregnancy outcomes and fetal brain development via modulation of BDNF/Bax-Bcl2/5-HT pathways in rats.
Article in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prenatal Exposure to Anxiolytics: A Critical Review on Brain Development and Neurobehavioral Manifestations in Offspring.Neurotoxicity research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Pregnancy presents a critical period during which the use of antidepressants requires cautious evaluation, especially due to the high incidence of depression in women of reproductive age. Vortioxetine hydrobromide (VOX), a newer multimodal antidepressant, is increasingly favored for its improved efficacy and tolerability. However, its safety profile during gestation and its potential long-term impact on fetal brain development remain insufficiently explored. This study aimed to assess the reproductive and developmental neurotoxicity of VOX administered at clinically relevant doses during pregnancy using a Wistar rat model. Pregnant dams received daily oral doses of either 1 mg/kg or 2 mg/kg of VOX from gestation day (GD) 6 to 21. On GD 21, the dams were euthanized, and fetuses along with placental tissues were collected for further analysis. Fetal brains underwent morphological, neurochemical, and histopathological evaluations. Exposure to VOX at the higher dose led to significant maternal and fetal toxicity, marked by reduced maternal weight gain, smaller litter sizes, and decreased fetal and placental weights. Notably, adverse neurodevelopmental outcomes were observed, including reduced fetal brain dimensions, cortical and hippocampal thinning, altered levels of brain-derived neurotrophic factor (BDNF), disrupted monoaminergic neurotransmitter levels (serotonin, dopamine, and norepinephrine), elevated apoptotic markers (Bax/Bcl-2 ratio), and increased acetylcholinesterase activity. These findings suggest that prenatal VOX exposure disrupts essential neurodevelopmental pathways, particularly those involving BDNF and monoaminergic signaling, potentially leading to persistent alterations in brain development. This is the first study to systematically demonstrate the developmental neurotoxicity of VOX, emphasizing the urgent need for further investigation into its safety during pregnancy.
Indexed as
Identifiers
40615562What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.